For the quarter ending 2026-03-31, KRYS had $5,009K increase in cash & cash equivalents over the period. $73,234K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 55,932 | 51,400 | 79,364 | 74,067 |
| Gain from sale of priority review voucher | - | 0 | - | - |
| Deferred tax asset | - | -1,835 | 24,680 | - |
| Depreciation | 1,522 | 1,562 | 1,403 | 2,759 |
| Accretion on marketable securities | -576 | -637 | -325 | 464 |
| Amortization of operating lease right-of-use assets | 204 | 200 | 209 | 418 |
| Stock-based compensation expense, net | 13,609 | 13,764 | 13,153 | 27,597 |
| Realized gain on investments | 529 | 404 | 1,293 | 4,256 |
| Other, net | 136 | 289 | -295 | 690 |
| Accounts receivable, net | -58 | -2,492 | 17,923 | 6,693 |
| Inventory | 243 | 1,058 | 4,713 | 515 |
| Prepaid taxes | -3,365 | 2,286 | 10,103 | - |
| Prepaid expenses and other current assets | 1,699 | -2,041 | 1,354 | 2,957 |
| Lease liability | -227 | -165 | -155 | -258 |
| Other long-term liabilities | 1,435 | 562 | 350 | 1,368 |
| Accounts payable | 1,022 | -183 | -4,020 | 5,029 |
| Accrued rebates | 12,685 | 2,310 | 4,124 | 14,834 |
| Accrued expenses and other current liabilities | -6,312 | 5,786 | 5,917 | 2,401 |
| Accrued legal settlement | 0 | 0 | 0 | -31,250 |
| Net cash provided by operating activities | 80,382 | 77,508 | 39,659 | 83,698 |
| Proceeds from disposal of assets | 0 | 0 | 0 | 435 |
| Proceeds from sale of priority review voucher | - | 0 | - | - |
| Purchases of property and equipment | 7,148 | 2,139 | 1,704 | 8,108 |
| Purchases of investments | 160,033 | 72,462 | 98,373 | 251,705 |
| Maturities of available-for-sale securities | - | - | 289,875 | - |
| Maturities of investments | 103,598 | 181,555 | - | 194,084 |
| Net cash (used in) investing activities | -63,583 | 11,163 | -4,286 | -65,294 |
| Proceeds from issuance of common stock, net | - | 0 | - | - |
| Proceeds from exercise of stock options | 6,501 | 15,689 | 3,714 | 3,258 |
| Taxes paid for employee tax withholding related to restricted stock units and taxes paid related to settlement of restricted stock awards-Restricted Stock Units RSU | 16,960 | 23 | 5 | 12,116 |
| Taxes paid for employee tax withholding related to restricted stock units and taxes paid related to settlement of restricted stock awards-Restricted Stock | 0 | 0 | 0 | 1,812 |
| Net cash (used in) financing activities | -10,459 | 15,666 | 3,709 | -10,670 |
| Effect of exchange rate changes on cash and cash equivalents | -1,331 | -637 | -307 | 1,230 |
| Net increase (decrease) in cash and cash equivalents | 5,009 | 103,700 | 38,775 | 8,964 |
| Cash and cash equivalents at beginning of period | 496,304 | 392,604 | 344,865 | - |
| Cash and cash equivalents at end of period | 501,313 | 496,304 | 392,604 | - |
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)